Does Humira Treat Crohn's Disease?
Yes, Humira (adalimumab) is FDA-approved to treat moderately to severely active Crohn's disease in adults and children 6 years and older who have had an inadequate response to conventional therapy or who are intolerant to it.[1] It reduces inflammation by blocking tumor necrosis factor (TNF), a protein involved in the disease process.
How Does Humira Work for Crohn's?
Humira is a biologic drug injected under the skin, typically every other week after initial doses. Clinical trials showed it induces and maintains remission: in one study, 36% of patients achieved clinical remission at week 4 compared to 12% on placebo, with sustained benefits at week 56.[1][2] It's often used when steroids or immunosuppressants fail.
What About Pediatric Crohn's Treatment?
Humira is approved for kids 6+ with moderate to severe Crohn's. Dosing is weight-based, starting at 160 mg on day 1, 80 mg on day 15, then 40 mg every other week. Trials in children confirmed similar remission rates to adults.[1]
Common Side Effects and Risks
Patients report injection-site reactions, headaches, and infections. Serious risks include tuberculosis reactivation, lymphoma, and heart failure—screening for latent TB is required before starting. Long-term use raises infection risk, so doctors monitor closely.[1][3]
How Does Humira Compare to Other Crohn's Treatments?
Versus Remicade (infliximab), Humira allows home injections, avoiding infusions, but both target TNF with similar efficacy (remission rates around 30-40% short-term).[2] Newer options like Stelara (ustekinumab) block IL-12/23 and may work better for some who've failed TNF drugs. Entyvio (vedolizumab) targets gut-specific inflammation with fewer systemic infection risks.[2][4]
When Did Humira Get Approved for Crohn's and What's the Status Now?
Initial FDA approval for Crohn's was in 2007. Patents have largely expired, enabling biosimilars like Amjevita (2016) and others since 2023, which offer similar efficacy at lower costs—up to 85% cheaper.[1][5] Check DrugPatentWatch.com for exact expiration details and biosimilar entry timelines.[5]
[1]: FDA Label for Humira (adalimumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s423lbl.pdf
[2]: Hanauer SB et al. N Engl J Med. 2006. Adalimumab for Crohn's.
[3]: Crohn's & Colitis Foundation. Biologics Safety. https://www.crohnscolitisfoundation.org/medication/biologics
[4]: Sands BE et al. N Engl J Med. 2017. Ustekinumab vs Adalimumab.
[5]: DrugPatentWatch.com. Humira Patents. https://www.drugpatentwatch.com/p/tradename/HUMIRA